Get the Stockscreener App
88.86
1.06%
-0.95
After Hours:
88.86
Henry Schein Inc stock is traded at $88.86, with a volume of 671.80K.
It is down -1.06% in the last 24 hours and up +0.83% over the past month.
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.
See More
Previous Close:
$89.81
Open:
$89.5
24h Volume:
671.80K
Relative Volume:
0.56
Market Cap:
$9.90B
Revenue:
$13.38B
Net Income/Loss:
$418.00M
P/E Ratio:
26.84
EPS:
3.3112
Net Cash Flow:
$391.00M
1W Performance:
+0.38%
1M Performance:
+0.83%
6M Performance:
+14.51%
1Y Performance:
+31.18%
1-Day Range:
$88.71
$89.99
1-Week Range:
$88.61
$91.69
52-Week Range:
$61.95
$92.18
Henry Schein Inc Stock (HSIC) Company Profile
Name
Henry Schein Inc
Sector
Industry
Phone
(631) 843-5500
Address
135 DURYEA RD, MELVILLE, NY
Compare HSIC vs MCK, COR, CAH, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HSIC
Henry Schein Inc
|
88.86 | 10.01B | 13.38B | 418.00M | 391.00M | 3.3112 |
MCK
Mckesson Corp
|
889.12 | 105.86B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
324.69 | 63.15B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
240.49 | 57.49B | 250.74B | 1.55B | 4.39B | 6.5398 |
AHG
Akso Health Group Adr
|
0.8168 | 726.49M | 14.85M | -136.07M | 7.25M | -0.4726 |
Henry Schein Inc Stock (HSIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-26 | Initiated | BTIG Research | Neutral |
| Apr-15-26 | Initiated | Citigroup | Buy |
| Feb-23-26 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Aug-26-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-25-25 | Downgrade | Stifel | Buy → Hold |
| Jul-14-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-14-25 | Initiated | Wells Fargo | Equal Weight |
| Jan-06-25 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-04-24 | Initiated | Mizuho | Neutral |
| Jul-22-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-12-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-10-23 | Upgrade | Stifel | Hold → Buy |
| Aug-08-22 | Upgrade | UBS | Sell → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Neutral |
| Jun-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| Jan-31-22 | Initiated | Morgan Stanley | Underweight |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Oct-01-21 | Resumed | Credit Suisse | Neutral |
| Feb-08-21 | Resumed | Piper Sandler | Overweight |
| Jan-04-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-03-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Apr-07-20 | Upgrade | Goldman | Neutral → Buy |
| Apr-02-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-20 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-02-20 | Upgrade | Evercore ISI | Underperform → In-line |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-30-19 | Initiated | Wolfe Research | Underperform |
| May-15-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-18-19 | Initiated | Guggenheim | Buy |
| Jan-17-19 | Initiated | UBS | Sell |
| Jan-03-19 | Downgrade | Evercore ISI | In-line → Underperform |
| Jan-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-08-18 | Reiterated | Barrington Research | Outperform |
| Oct-25-18 | Downgrade | Edward Jones | Hold → Sell |
| Oct-19-18 | Resumed | Goldman | Neutral |
| Oct-04-18 | Reiterated | Robert W. Baird | Outperform |
| Aug-07-18 | Reiterated | Stifel | Hold |
| Apr-24-18 | Downgrade | Goldman | Buy → Neutral |
| Apr-04-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
View All
Henry Schein Inc Stock (HSIC) Latest News
Precision Trading with Henry Schein Inc. (HSIC) Risk Zones - Stock Traders Daily
Henry Schein stock rises on a new distribution deal - AD HOC NEWS
Henry Schein to Present at Baird Global Healthcare Conference - Dentistry Today
Henry Schein to Distribute Applied BioCode's MDx-3000 System in US - marketscreener.com
Applied BioCode Announces Distribution Agreement with Henry Schein - Yahoo Finance
Henry Schein to Participate in Upcoming Investor Conference in September - Business Wire
How Investors May Respond To Henry Schein (HSIC) Distributing DermaSensor’s Skin Cancer Detection Device - webull.com
Henry Schein stock gains after strong Q2 2026 results and raised outlook - ad-hoc-news.de
Henry Schein, Inc. (HSIC) Stock Analysis: Unveiling a 9.33% Upside Opportunity in the Medical Distribution Sector - DirectorsTalk Interviews
Henry Schein stock gains institutional support as new diagnostic partnership advances strategy - AD HOC NEWS
Henry Schein Inc. stock outperforms competitors despite losses on the day - MarketWatch
Henry Schein Inc. helps children start the school year - Reading Eagle
Henry Schein stock rises after Q2 earnings beat - AD HOC NEWS
Henry Schein (HSIC) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
Why Is Henry Schein (HSIC) Up 0.9% Since Last Earnings Report? - easternprogress.com
Henry Schein shares technical analysis: Resistance test at $92.68 in focus - Traders Union
Why Henry Schein (HSIC) is a Top Growth Stock for the Long-Term - easternprogress.com
Is Henry Schein (HSIC) Stock Undervalued Right Now? - Yahoo Finance
Henry Schein (HSIC) Looks Modestly Undervalued, Is More Upside Still Available? - Yahoo Finance
Growth Trajectory and Attractive Valuations Support Henry Schein’s (HSIC) Bullish Thesis - Yahoo Finance
Henry Schein, Inc. (HSIC) Stock Analysis: Exploring a 9.68% Upside Potential in the Medical Distribution Sector - DirectorsTalk Interviews
Henry Schein, Inc. (HSIC) Stock Report: Analyst Consensus Points to 10.95% Potential Upside - DirectorsTalk Interviews
Henry Schein Inc. stock outperforms competitors on strong trading day - MarketWatch
Henry Schein (HSIC) Q1 2026 Earnings Call Transcript - fortune.com
Henry Schein stock holds steady as 2026 outlook is raised and Q2 earnings beat - Ad-hoc-news.de
What Are Wall Street Analysts' Target Price for Henry Schein Stock? - Yahoo Finance
Is HSIC Worth Buying as Growth Improves but Execution Risks Persist? - TradingView
Henry Schein, Special Olympics re-up partnership - HME News
Henry Schein (NASDAQ:HSIC) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
Tranche Update on Henry Schein, Inc.'s Equity Buyback Plan announced on December 13, 2018. - marketscreener.com
BTIG Adjusts Price Target on Henry Schein to $110 From $100, Maintains Buy Rating - marketscreener.com
Henry Schein and Special Olympics Renew Partnership Through 2030 - Orthodontic Products
Henry Schein stock holds steady as higher-margin Q2 2026 lifts guidance - AD HOC NEWS
Building a healthier future together: Henry Schein and Special Olympics renew partnership through 2030 - Special Olympics
HSIC Raises 2026 Outlook as Sales and Margin Momentum Accelerates - TradingView
Empowered Funds LLC Has $851,000 Position in Henry Schein, Inc. $HSIC - MarketBeat
Buckland Partners Management Co LLC Makes New Investment in Henry Schein, Inc. $HSIC - MarketBeat
Henry Schein stock holds near a 52-week high after a Buy upgrade - Ad-hoc-news.de
Henry Schein, Inc. (HSIC) Stock Analysis: Exploring Growth Potential Amidst a 8.68% Upside - DirectorsTalk Interviews
Henry Schein (NASDAQ:HSIC) Rating Increased to Buy at Wall Street Zen - MarketBeat
How Henry Schein’s Strong Q2 Earnings and Higher 2026 Sales Outlook Will Impact Henry Schein (HSIC) Investors - simplywall.st
Form 144 | Henry Schein(HSIC.US) Insider Proposes to Sell 3.18 Million in Common Stocks - Moomoo
Henry Schein (HSIC) insider Bergman plans $3.18M sale under Form 144 - Stock Titan
HSIC|Henry Schein Inc|Price:90.000|Chg%:+0.230 - tradingkey.com
5 Insightful Analyst Questions From Henry Schein’s Q2 Earnings Call - Yahoo Finance
Henry Schein, Inc. (HSIC) Stock Forecasts - Yahoo Finance
Why Henry Schein's (NASDAQ:HSIC) Earnings Are Better Than They Seem - Moomoo
Henry Schein's (NASDAQ:HSIC) Earnings Seem To Be Promising - simplywall.st
Henry Schein (HSIC) Q2 2026 Earnings Call Transcript - AOL.com
Should Henry Schein’s (HSIC) Upgraded 2026 Outlook and New Structure Require Action From Investors? - webull.com
Should Value Investors Buy Henry Schein (HSIC) Stock? - finance.yahoo.com
Henry Schein Inc Stock (HSIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.68%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):